ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report) will release its earnings data on Friday, April 26th.
ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report) last issued its quarterly earnings results on Friday, April 12th. The company reported ($0.78) earnings per share (EPS) for the quarter. On average, analysts expect ASLAN Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
ASLAN Pharmaceuticals Stock Performance
Shares of NASDAQ:ASLN opened at $0.47 on Thursday. The stock’s 50-day moving average price is $0.61 and its two-hundred day moving average price is $0.72. ASLAN Pharmaceuticals has a 12-month low of $0.39 and a 12-month high of $4.69. The firm has a market cap of $7.68 million, a price-to-earnings ratio of -0.17 and a beta of 1.45.
Analyst Ratings Changes
Check Out Our Latest Analysis on ASLN
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.
Featured Stories
- Five stocks we like better than ASLAN Pharmaceuticals
- Compound Interest and Why It Matters When Investing
- High-Yield Texas Instruments Could Hit New Highs Soon
- Stock Market Sectors: What Are They and How Many Are There?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Insider Trades May Not Tell You What You Think
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.